Recro Pharma Secures $100 Million Credit Facility Mon, 20 Nov 2017 12:00:00 +0000 Proceeds Provide Funding for IV Meloxicam 30 mg Approval Milestone. Interest-only Structure Allows for Reinvestment of CDMO Cash Flows in Value Accretive Commercial Activities. Substantial Reduction in ...
Recro Pharma reports 3Q loss Thu, 09 Nov 2017 14:37:44 +0000 On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 48 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Recro Pharma Reports Third Quarter 2017 Financial Results Thu, 09 Nov 2017 12:00:00 +0000 NDA Submission for IV Meloxicam Accepted by U.S. FDA for Review; PDUFA Date Set for May 26, 2018. Strong Gainesville Manufacturing Performance; Third Quarter 2017 Revenues of $17.1 Million.
Recro Pharma to Present at Upcoming Investor Conferences Wed, 08 Nov 2017 12:00:00 +0000 MALVERN, Pa., Nov. 08, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...
Recro Pharma Reports Inducement Grants for New Staff Tue, 31 Oct 2017 11:00:00 +0000 MALVERN, Pa., Oct. 31, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced the expansion ...
ETFs with exposure to Recro Pharma, Inc. : October 9, 2017 Mon, 09 Oct 2017 15:59:06 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Recro Pharma, Inc. Here are 5 ETFs with the largest exposure to REPH-US. Comparing the performance and risk of Recro Pharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more
(Read more...)
Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Fri, 06 Oct 2017 13:12:02 +0000 Categories: Yahoo FinanceGet free summary analysis Recro Pharma, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 16.93 million, Net Earnings of USD -8.86 million. Gross margins narrowed from 41.01% to 34.49% compared to the same period last year, operating (EBITDA) margins now -33.55% from -12.22%. Change in operating ... Read more
(Read more...)
Recro Pharma to Participate in Upcoming Investor Conferences Thu, 05 Oct 2017 21:00:00 +0000 MALVERN, Pa., Oct. 05, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that Gerri Henwood, ...
Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg Thu, 05 Oct 2017 11:00:00 +0000 MALVERN, Pa., Oct. 05, 2017-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today announced that the U.S. ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.